CWAM
LAB icon

Columbia Wanger Asset Management’s Standard BioTools LAB Stock Holding History

Columbia Wanger Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,777,282
Closed -$16M – 202
2016
Q2 		$16M Sell
1,777,282
-278,722
-14% -$2.62M 0.19% 157
2016
Q1 		$16.6M Buy
2,056,004
+267,231
+15% +$1.93M 0.18% 149
2015
Q4 		$19.3M Buy
+1,788,773
New +$17.6M 0.19% 150

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EA
Emerald Acquisition Seattle, Washington $51.8B AUM
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Columbia Wanger Asset Management's LAB Position: Q3 2016 in Review

Columbia Wanger Asset Management sold out of Standard BioTools (LAB) in Q3 2016, closing a stake of 1,777,282 shares — an estimated $16M sold.

Columbia Wanger Asset Management first reported a position in LAB in Q4 2015 and held it in 3 quarters. The position peaked at $19.3M in Q4 2015. 98 funds tracked by Wall St. Rank hold LAB as of Q3 2016.

  • Columbia Wanger Asset Management reported no remaining Standard BioTools position as of Q3 2016 after selling out during the quarter.
  • Columbia Wanger Asset Management sold 1,777,282 Standard BioTools shares in Q3 2016, an estimated $16M.
  • Columbia Wanger Asset Management first reported a position in Standard BioTools in Q4 2015 and held it in 3 quarters.
  • Columbia Wanger Asset Management's Standard BioTools position peaked at $19.3M in Q4 2015.
  • 98 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2016.

Based on Columbia Wanger Asset Management's 13F filing for Q3 2016, filed 10 Nov 2016.